1. 1) Michel C, Scosyrev E, Petrin M, Schmouder R. Can disproportionality analysis of post-marketing case reports be used for comparison of drug safety profiles? Clin. Drug Investig., 37, 415–422 (2017).
2. 2) Singh A, Bhatt P. Comparative evaluation of adverse drug reaction reporting forms for introduction of a spontaneous generic ADR form. J. Pharmacol. Pharmacother., 3, 228–232 (2012).
3. 3) Alves C, Marques FB, Macedo AF. Drug-safety alerts issued by regulatory authorities: usefulness of meta-analysis in predicting risks earlier. Eur. J. Clin. Pharmacol., 70, 745–756 (2014).
4. 4) Alves C. The role of meta-analysis in pharmacovigilance: how best to combine different sources of evidence about harms? Universidade de Coimbra (2015).
5. 5) Tuccori M, Montagnani S, Capogrossosansone A, Mantarro S, Antonioli L, Fornai M, Blandizzi C. Adverse reactions to oncologic drugs: spontaneous reporting and signal detection. Expert Rev. Clin. Pharmacol., 8, 61–75 (2015).